Codrituzumab-MMAE

  Cat. No.:  A152   Featured
Chemical Structure
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86-021-58447131
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
Codrituzumab-MMAE, is an antibody-drug conjugate composed of a anti-GPC3 monoclonal antibody and a cytotoxic tubulin polymerase inhibitor conjugated through MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) type linker.
Cas No.:
pH value: Corresponds to reference standard: PASS
Non-reduced CE-SDS: >95%
SEC-HPLC: >95%
Isoelectric Point: Corresponds to reference standard
Osmolality: Corresponds to reference standard: PASS
Peptide mapping: Corresponds to reference standard: PASS
N-terminal sequence: Corresponds to reference standard: PASS
Description: Codrituzumab-MMAE, is an antibody-drug conjugate composed of a anti-GPC3 monoclonal antibody and a cytotoxic tubulin polymerase inhibitor conjugated through MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) type linker.
MSDS
Cat. No. Product name Field of application
A901 Losatuxizumab Losatuxizumab (ABT-806) is an anti-EGFR monoclonal antibody. Losatuxizumab binds to EGFR with EC50s of 0.96 nM for EGFR wild-type, 0.09 nM for EGFRC271A,C283A, 0.12 nM for EGFRvIII, 0.66 nM for EGFR1-501. Losatuxizumab can be used for research of EGFR-expressing cancers.
A900 Serclutamab Serclutamab is a humanized chimeric antibody targeting EGFR IgG1-κ. Mainly expressed by CHO (Chinese Hamster Ovary) cells.
A899 Demupitamab
A898 Abbott patent anti-EPO Receptor
A897 VasGene patent anti-EphB4
A896 Morphosys patent anti-EphB4
A895 Genentech patent anti-EphB2
A894 Ifabotuzumab
A893 Adecatumumab Adecatumumab (Anti-Human EPCAM Recombinant Antibody; MT201) is a full human monoclonal antibody of the IgG1 isotype, targeting human EpCAM. Adecatumumab is expressed in almost all adenocarcinomas, and its activity is not dependent of K-Ras status.
A892 Oportuzumab
X